Welcome to our dedicated page for OMADA HEALTH SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. ownership was reported by Divisadero Street-affiliated filers showing shared beneficial ownership of 5,056,517 common shares representing 8.7% of the class and affiliated entities holding 3,656,064 shares representing 6.3%.
The filing states these securities are directly owned by advisory clients of Divisadero Street Capital Management, LP, and includes a disclaimer that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The schedule is signed by William Zolezzi.
Omada Health, Inc. received an amended Schedule 13G/A reflecting updated ownership by several investors in its common stock. U.S. Venture Partners X, L.P., USVP X Affiliates, L.P., and Presidio Management Group X, L.L.C. each report beneficial ownership of 0 shares, representing 0% of the class.
By contrast, Casey M. Tansey, through a trust for his benefit, reports beneficial ownership of 138,082 shares of common stock, with sole voting and dispositive power over those shares. This represents 0.2% of Omada Health’s common stock, based on 57,908,047 shares outstanding as of November 5, 2025. All Reporting Persons state that they own 5% or less of the class.
Omada Health, Inc. and Andreessen Horowitz-affiliated funds report their ownership positions in Omada’s common stock as of December 31, 2025. Andreessen Horowitz Fund IV, L.P. holds 3,157,951 shares, representing 5.5% of the company’s common stock, while AH Parallel Fund IV, L.P. holds 302,978 shares, or 0.5%.
Marc L. Andreessen reports beneficial ownership of 3,540,847 shares, and Benjamin A. Horowitz reports 3,538,143 shares, each representing 6.1% of the outstanding common stock. These percentages are based on 57,908,047 shares outstanding as of November 5, 2025, and reflect voting and dispositive powers held through various Andreessen Horowitz entities and family trusts.
Omada Health, Inc. chief executive Sean P. Duffy, who also serves as a director, reported several stock option exercises and related share sales. On January 12, 2026, he exercised 230,479 stock options at an exercise price of $2.55 per share and sold 139,989 common shares at a weighted average price of $15.3471 and 90,490 shares at a weighted average price of $15.9877. On January 13, 2026, he exercised an additional 40,796 options at $2.55 and sold 40,796 shares at a weighted average price of $15.9519. The options exercised were non-qualified stock options scheduled to expire on January 27, 2026 and are fully vested. Following these transactions, Duffy directly owns 126,644 common shares and has an additional 861,109 shares reported as indirectly owned through family trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. furnished an update on its recent performance by announcing preliminary, unaudited revenue for the fourth quarter and full fiscal year ended December 31, 2025. The company disclosed this information in connection with a public webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The preliminary figures are subject to completion of Omada’s year-end closing procedures and its annual independent audit and may be adjusted. The revenue details are contained in a press release attached as Exhibit 99.1, which is furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC reports.
Omada Health, Inc. director Jonathan D. Root received 915 restricted stock units (RSUs) of Common Stock on January 5, 2026. The award was granted at a price of $0 per share under Omada Health’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents the right to receive one share of Common Stock, with settlement to occur on a date Mr. Root selects under the program or as otherwise provided by the program. Following this grant, he beneficially owns 179,293 shares of Common Stock directly.
Omada Health director Trevor Fetter reported an equity award on Form 4. On January 5, 2026, he received 991 restricted stock units (RSUs) of Omada Health, Inc. common stock at a price of $0 per share under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents one share of common stock, with settlement to occur on a date he selects under the program or as otherwise provided by the program.
After this grant, Fetter beneficially owns 11,696 shares directly and 111,200 shares indirectly through a limited liability company of which he is the sole member.
Omada Health, Inc. director Jeryl L. Hilleman received an equity grant of 1,601 shares of Common Stock on 01/05/2026, reported as an acquisition at a price of $0 per share. The filing explains this represents restricted stock units (RSUs) granted under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees, with each RSU convertible into one share of common stock at settlement. Following this grant, Hilleman beneficially owns 12,794 shares of Omada Health common stock in direct ownership.
Omada Health, Inc. director Jeryl L. Hilleman reported an updated equity holding following a restricted stock unit grant and a correction to a prior filing. On 10/05/2025, Hilleman was granted 1,081 restricted stock units (RSUs) of Omada Health common stock under the company’s Non-Employee Director Compensation Program, in lieu of cash retainer fees, at a reported price of $0 per share. Each RSU represents the right to receive one share of common stock, with settlement timing determined under the program or as selected by the director. After this transaction, Hilleman beneficially owned 11,193 shares of common stock. The amendment notes that the original report overstated both the amount of securities acquired and beneficially owned by 45 shares, and this filing corrects those errors.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported a sale of 4,211 shares of the company’s common stock on 12/10/2025 at a weighted average price of $15.3657 per share. The sale was coded as an open market or private sale transaction and was made pursuant to a Rule 10b5-1 trading plan adopted by Cook on 08/15/2025.
The transaction was executed in multiple trades at prices ranging from $15.24 to $15.55 per share. Following this sale, Cook beneficially owns 57,566 shares of Omada Health common stock in direct ownership.